The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Celgene
Research Funding - Celgene (Inst)

Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.
 
Pierre Fenaux
No Relationships to Disclose
 
Valeria Santini
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Geron; Gilead Sciences; Menarini; Novartis
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Bristol-Myers Squibb; Geron; Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals
 
Amer Methqal Zeidan
Honoraria - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Trovagene
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Rena Buckstein
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Takeda
 
Dimana Miteva
Employment - Bristol-Myers Squibb
 
Karen Keeperman
Employment - Bristol-Myers Squibb
 
Natalia Holot
Employment - Bristol-Myers Squibb
 
Jennie Zhang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Christina Hughes
Employment - Bristol-Myers Squibb
 
Barbara Rosettani
Employment - Bristol-Myers Squibb
 
Aylin Yucel
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Uwe Platzbecker
Honoraria - Celgene/Jazz
Consulting or Advisory Role - Celgene/Jazz
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene